Report Details:
15 Companies Covered
128 Pages
Market Research Future (MRFR) has published a comprehensive research report on the Global Personalized Medicine Market, covering the forecast period from 2025 to 2035. According to the analysis, the Personalized Medicine Market was valued at USD 596.7 billion in 2024 and is projected to grow significantly, reaching USD 1,165.1 billion by 2035, registering a compound annual growth rate (CAGR) of 6.27% during the forecast period.
MRFR identifies Roche (CH), Novartis (CH), Thermo Fisher Scientific (US), Illumina (US), GSK (GB), Bristol-Myers Squibb (US), Pfizer (US), Merck & Co. (US), and Amgen (US) as the key players operating in the Global Personalized Medicine Market.
Market Highlights
The Global Personalized Medicine Market is accounted for to register a CAGR of 6.27% during the forecast period and is estimated to reach USD 1,165.1 billion by 2035.
One of the main drivers propelling market expansion is the rising incidence of chronic illnesses, such as cancer, heart disease, diabetes, and neurological disorders. The demand for precision medicine solutions is rising globally as healthcare professionals adopt more individualized treatment strategies that enhance therapeutic outcomes while reducing side effects.
Technological developments in next-generation sequencing (NGS), genomics, and molecular diagnostics are drastically changing the field of personalized medicine. Clinicians can now administer highly tailored medicines based on unique patient features thanks to ongoing advancements in genetic profiling and biomarker identification, which improves treatment accuracy and clinical outcomes.
The industry is expanding thanks to the increasing integration of advanced data analytics, machine learning, and artificial intelligence (AI). By effectively processing massive amounts of genomic and clinical data, AI-powered platforms are boosting illness diagnosis, patient classification, treatment selection, and drug discovery procedures, increasing the overall efficacy of customized healthcare.
Innovation is also being promoted throughout the sector by encouraging regulatory actions and rising investments in pharmaceutical and biotechnology research. While increasing patient awareness of precision medicine continues to generate positive chances for market growth, regulatory authorities are expediting the approval process for innovative treatments.
Segment Analysis
The Global Personalized Medicine Market is segmented based on Product, Application, End-User, and Region.
By Product, the market includes Personalized Medicine Diagnostics, Personalized Medicine Therapeutics, Personalized Medical Care, and Personalized Nutrition and Wellness. Personalized Medicine Diagnostics hold the largest market share owing to their critical role in identifying genetic variations, biomarkers, and disease risks that enable customized treatment decisions. Personalized Medicine Therapeutics represent the fastest-growing segment, driven by increasing adoption of targeted therapies, gene-based treatments, and precision drug development across multiple disease areas.
By Application, the market includes Oncology, CNS, Immunology, Respiratory, and Others. Oncology dominates the market due to widespread adoption of precision oncology, companion diagnostics, and targeted cancer therapies that improve treatment efficacy and patient survival rates. CNS (Central Nervous System) is the fastest-growing application segment as advancements in neurogenomics and personalized neurological therapies gain momentum for treating Alzheimer's disease, Parkinson's disease, and other neurological disorders.
By End-User, the market includes Hospitals, Diagnostic Centers, Research & Academic Institutes, and Others. Hospitals account for the largest market share owing to their comprehensive healthcare infrastructure, integrated diagnostic capabilities, and increasing implementation of personalized treatment protocols. Diagnostic Centers are the fastest-growing segment due to rising demand for genetic testing, biomarker analysis, and precision diagnostic services supporting early disease detection and individualized treatment planning.
Region Analysis
Regionally, the Global Personalized Medicine Market is witnessing strong growth across major regions due to advancements in genomics, increasing healthcare investments, and expanding adoption of precision medicine.
North America holds the largest market share, supported by advanced healthcare infrastructure, strong biotechnology research, favorable regulatory frameworks, and substantial investments in precision medicine. The United States dominates the regional market due to the presence of leading pharmaceutical and biotechnology companies, extensive genomic research, and increasing adoption of AI-enabled healthcare technologies.
Europe represents the second-largest market, driven by an aging population, increasing healthcare digitization, and supportive regulatory initiatives promoting personalized medicine. Countries including Germany, the United Kingdom, and France are major contributors due to strong pharmaceutical research capabilities and growing investments in precision healthcare.
Asia-Pacific is expected to be the fastest-growing regional market during the forecast period. Rapid healthcare modernization, increasing government investments in biotechnology, growing awareness of personalized therapies, and expanding genomic research activities in China, India, Japan, and South Korea are driving significant market expansion across the region.
The Rest of the World, including the Middle East, Africa, and South America, is also witnessing increasing adoption of personalized medicine as governments invest in healthcare infrastructure, biotechnology research, and advanced diagnostic capabilities. Rising chronic disease prevalence and improving access to precision healthcare solutions are expected to support long-term market growth across these regions.
Key Findings of the Study
- The Global Personalized Medicine Market is projected to grow at a CAGR of 6.27% during the forecast period.
- The market is expected to reach USD 1,165.1 billion by 2035, driven by advancements in genomics, precision diagnostics, and targeted therapies.
- Personalized Medicine Diagnostics hold the largest market share, while Personalized Medicine Therapeutics are witnessing the fastest growth.
- Oncology remains the dominant application segment, while CNS is emerging as the fastest-growing therapeutic area.
- Hospitals account for the largest end-user segment, whereas Diagnostic Centers are experiencing the fastest growth due to increasing demand for genetic testing and personalized diagnostics.
- North America dominates the global market owing to advanced healthcare infrastructure, strong R&D investments, and favorable regulatory support.
- Asia-Pacific is expected to witness the fastest growth due to expanding biotechnology investments, healthcare modernization, and increasing adoption of personalized medicine.
- Advancements in genomic sequencing, AI-powered diagnostics, molecular testing technologies, and increasing investment in pharmaceutical R&D are major factors driving market expansion.
- Roche, Novartis, Thermo Fisher Scientific, Illumina, Pfizer, Merck & Co., Bristol-Myers Squibb, GSK, and Amgen remain among the leading companies driving innovation and competition in the global personalized medicine market.
